Surgical excision is the gold standard therapy for clinically localized renal masses.
Nevertheless, prognostication of the natural history of untreated renal cell carcinoma (RCC) remains a clinical challenge. While active surveillance (AS) has emerged as a viable treatment option in select patients with localized tumors and significant competing mortality risks, long term follow up data to assess the risk of disease progression are limited. We present a case of a localized, clinical stage T2 renal mass progressing to regional and systemic disease over 6 years, demonstrating that kinetics of disease progression may be prolonged and are yet to be fully understood.
Written by:
Sterious S, Smaldone MC, Plimack E, Uzzo RG, Canter D, Kutikov A. Are you the author?
Department of Surgucal Oncology, Division of Urological Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA.
Reference: Can J Urol. 2012 Dec;19(6):6578-80.
PubMed Abstract
PMID: 23228296
UroToday.com Renal Cancer Section
